APOE and alzheimer's disease: Neuroimaging of metabolic and cerebrovascular dysfunction

Jason A. Brandon, Brandon C. Farmer, Holden C. Williams, Lance A. Johnson

Research output: Contribution to journalShort surveypeer-review

38 Scopus citations

Abstract

Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for late onset Alzheimer's Disease (AD), and is associated with impairments in cerebral metabolism and cerebrovascular function. A substantial body of literature now points to E4 as a driver of multiple impairments seen in AD, including blunted brain insulin signaling, mismanagement of brain cholesterol and fatty acids, reductions in blood brain barrier (BBB) integrity, and decreased cerebral glucose uptake. Various neuroimaging techniques, in particular positron emission topography (PET) and magnetic resonance imaging (MRI), have been instrumental in characterizing these metabolic and vascular deficits associated with this important AD risk factor. In the current mini-review article, we summarize the known effects of APOE on cerebral metabolism and cerebrovascular function, with a special emphasis on recent findings via neuroimaging approaches.

Original languageEnglish
Article number180
JournalFrontiers in Aging Neuroscience
Volume10
Issue numberJUN
DOIs
StatePublished - Jun 14 2018

Bibliographical note

Publisher Copyright:
© 2018 Brandon, Farmer, Williams and Johnson.

Keywords

  • Alzheimer's Disease (AD)
  • ApoE
  • Apolipoprotein E
  • Brain
  • Cerebral
  • Imaging
  • Metabolism
  • Neurodegeneration

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience

Fingerprint

Dive into the research topics of 'APOE and alzheimer's disease: Neuroimaging of metabolic and cerebrovascular dysfunction'. Together they form a unique fingerprint.

Cite this